Pulse Biosciences (NASDAQ:PLSE) Shares Pass Below 50-Day Moving Average - Here's What Happened

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report)'s share price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $19.37 and traded as low as $17.66. Pulse Biosciences shares last traded at $17.87, with a volume of 196,194 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research note on Thursday, January 2nd.

Pulse Biosciences Stock Up 2.7 %

The business has a 50 day simple moving average of $19.32 and a 200-day simple moving average of $18.44.

Insider Activity

In other Pulse Biosciences news, Director Robert W. Duggan purchased 55,256 shares of the stock in a transaction dated Friday, December 13th. The stock was acquired at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares in the company, valued at $727,207,358.06. This trade represents a 0.13 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Burke Thomas Barrett sold 50,000 shares of the business's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares in the company, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 71.50% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of Pulse Biosciences by 98.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock valued at $29,000 after acquiring an additional 838 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Pulse Biosciences by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock valued at $2,598,000 after purchasing an additional 1,092 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Pulse Biosciences by 44.4% during the 4th quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company's stock worth $126,000 after acquiring an additional 2,220 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Pulse Biosciences by 27.1% in the 4th quarter. Wells Fargo & Company MN now owns 11,315 shares of the company's stock valued at $197,000 after purchasing an additional 2,416 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Pulse Biosciences during the fourth quarter worth approximately $44,000. Hedge funds and other institutional investors own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.